Gch1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
GCH1 (GTP Cyclohydrolase 1) is the rate-limiting enzyme in the biosynthesis of tetrahydrobiopterin (BH4), an essential cofactor for dopamine, norepinephrine, serotonin, and nitric oxide synthesis. Mutations in GCH1 cause dopa-responsive dystonia (DRD) and Segawa syndrome, and variants are associated with Parkinson's disease risk.
| Attribute | Value |
|---|---|
| Gene Symbol | GCH1 |
| Full Name | GTP Cyclohydrolase 1 |
| Alternative Names | GCH, GTPCH1 |
| Chromosomal Location | 14q22.2 |
| NCBI Gene ID | 2623 |
| Ensembl ID | ENSG00000131979 |
| UniProt ID | P30793 |
| OMIM | 600225 |
GCH1 encodes GTP cyclohydrolase I, the first and rate-limiting enzyme in the biosynthesis of tetrahydrobiopterin (BH4):
GCH1 is expressed in:
GCH1 mutations cause DRD (also known as Segawa syndrome):
GCH1 variants are associated with PD risk:
See DRD above - this is the same condition, historically called Segawa syndrome.
Inherited GCH1 deficiency causes:
| Treatment | Mechanism | Indication |
|---|---|---|
| Tetrahydrobiopterin (BH4) | Cofactor replacement | GCH1 deficiency, DRD |
| Sapropterin dihydrochloride | Synthetic BH4 | BH4 deficiency |
Ichinose H, et al. (1994). Mutations in the GTP cyclohydrolase I gene cause dopa-responsive dystonia. Nat Genet 8(3):236-242. PMID:7874165
Furukawa Y, et al. (1999). Genetic heterogeneity in dopa-responsive dystonia: Lessons from Japanese patients. J Neurol Neurosurg Psychiatry 67(3):323-328. PMID:10449551
Wu D, et al. (2018). Association between GCH1 polymorphisms and Parkinson's disease: A meta-analysis. Neurosci Lett 682:13-19. PMID:29807023
Lohn K, et al. (2017). GTP cyclohydrolase I in cardiovascular disease. Adv Pharmacol 78:185-222. PMID:28826565
Nagatsu T, Sawada M. (2006). Molecular mechanism of the relation of GCH1 and Parkinson's disease. Adv Neurol 99:85-89. PMID:16489132
The study of Gch1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Last updated: 2026-03-03
[1] Segawa M, Fukuda K, Nomura Y, Hoshino K. Dopa-responsive dystonia: pathophysiology and treatment. J Neurol. 2006;253(Suppl 7):VII35-VII40. DOI:10.1007/s00415-006-7008-1
[2] Furukawa Y, Kish SJ, Shannak K, et al. Dopa-responsive dystonia: a dramatic response to low-dose levodopa therapy. Neurology. 1999;52(2):362-368. DOI:10.1212/wnl.52.2.362
[3] Hwu WL, Wang PJ, Lee WT, et al. GTP cyclohydrolase I deficiency in a Chinese family with dopa-responsive dystonia. Brain Dev. 2000;22(Suppl 1):S105-S107. DOI:10.1016/s0387-7604(0000146-4.
[4]</mitti S, Lindsten T, Scherer DJ, et al. GTP cyclohydrolase I deficiency and parkinsonism. Neurology. 2001;56(9):1158-1161. DOI:10.1212/wnl.56.9.1158
[5] Jain S, Sievert LL, Longo LD. Genetic and molecular basis of dopa-responsive dystonia. Mol Genet Metab. 2005;86(4):385-391. DOI:10.1016/j.ymgme.2005.09.003